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Bacterial resistance against antibiotic treatment has become a major threat to public health. Antimicrobial peptides
(AMPs) have emerged as promising alternative agents for treatment of infectious diseases. This study characterizes
novel synthetic peptides sequentially derived from the AMP centrocin 1, isolated from the green sea urchin, for
their applicability as anti-infective agents.
The microbicidal effect of centrocin 1 heavy chain (CEN1 HC-Br), its debrominated analogue (CEN1 HC), the
C-terminal truncated variants of both peptides, i.e. CEN1 HC-Br (1–20) and CEN1 HC (1–20), as well as the cysteine
to serine substituted equivalent CEN1 HC (Ser) was evaluated using minimal microbicidal concentration assay. The
anti-inflammatory properties were assessed by measuring the inhibition of secretion of pro-inflammatory cytokines.
All the peptides tested exhibited marked microbicidal and anti-inflammatory properties. No difference in efficacy
was seen comparing CEN1 HC-Br and CEN1 HC, while the brominated variant had higher cytotoxicity. C-terminal
truncation of both peptides reduced salt-tolerability of the microbicidal effect as well as anti-inflammatory actions.
Also, serine substitution of cysteine residue decreased the microbicidal effect. Thus, from the peptide variants
tested, CEN1 HC showed the best efficacy and safety profile. Further, CEN1 HC significantly reduced bacterial counts
in two different animal models of infected wounds, while Staphylococcus aureus and methicillin-resistant S. aureus
(MRSA) failed to develop resistance against this peptide under continued selection pressure. In summary, CEN1 HC
appears a promising new antimicrobial agent, and clinical studies are warranted to evaluate the applicability of this
AMP for local treatment of infections in man.
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Infectious diseases are among the leading causes of
death worldwide. According to the World Health
Organization, acute infectious diseases account for 25%
of deaths globally and for 45% in developing countries,
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in any medium, provided the original work is pSeveral orders of magnitude higher is the number of
people who survive the initial infection but suffer from
conditions where microbes cause a chronic inflamma-
tion (Schmidt 2004). The treatment of infections has re-
cently been complicated due to emerging increase of
bacterial resistance towards conventional antibiotics.
The occurrence of MRSA in hospital environments has
been reported as a significant problem since its recogni-
tion over 50 years ago (Jevons 1961). In recent years, the
emergence of community-acquired strains has rapidly
grown, as in some settings, community-acquired MRSAOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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tions (Giordano et al. 2007). In addition, enterococci,
leading to surgical wound and urinary tract infections,
are becoming intrinsically resistant to many antibiotics.
Also, multi-drug resistant strains of Pseudomonas aeru-
ginosa are associated with severe adverse clinical out-
comes (Jones et al. 2005; Moet et al. 2007). Resistance
development is not confined to antibiotics only. Silver
products have been considered to carry a low risk of re-
sistance development, however burn wound studies have
demonstrated that bacteria, in particular P. aeruginosa,
may become resistant to silver sulfadiazine and silver ni-
trate (Vermeulen et al. 2007).
AMPs are receiving increased attention as potential
therapeutic candidates in infectious disease treatment.
AMPs are gene-encoded, ribosomally synthesised peptides
which are widespread in nature, and appear to be import-
ant defence molecules in all eukaryotic phyla. Most natu-
rally occurring AMPs carry a net positive charge
(i.e. cationic) and are composed of 12–50 residues where
close to 50% of them are hydrophobic (Hancock and
Diamond 2000; Teixeira et al. 2012). In membrane-like
environments AMPs tend to form amphipathic structures,
i.e. structures with separate hydrophobic and hydrophilic
domains. The positive charge of AMPs presumably
enables interactions with the negatively charged outer
leaflet of bacterial membranes and/or bacterial cell wall
components, whereas their amphipathic character causes
membrane permeabilization (Devine and Hancock 2002;
Teixeira et al. 2012). Notably, although AMPs are widely
distributed in nature and bacteria have been exposed to
these molecules for millions of years, widespread resist-
ance has not been reported (Fjell et al. 2012). Many AMPs
have also shown to possess favourable activities other than
bactericidal effect, such as anti-inflammatory properties
(Auvynet and Rosenstein 2009; Bowdish et al. 2005; Scott
and Hancock 2000). Based on these properties, AMPs
have emerged as novel promising agents for both topical
and systemic treatment of infectious diseases (Schuerholz
et al. 2012; Yount and Yeaman 2012).
Invertebrates are proving to be a rich source of AMPs,
possibly because of their more pronounced reliance on
innate immune functions in their defence against micro-
bial pathogens compared to vertebrates. Many of the
peptides isolated from marine species are structurally
unique, display significant biological activities and are
therefore expected to be useful drug leads (Sperstad
et al. 2011). In a previous study, we detected broad-
spectrum antibacterial activity in coelomocyte (blood
cell) extracts of the green sea urchin, S. droebachiensis
(Haug et al. 2002). Subsequently, an AMP named cen-
trocin 1 was isolated and characterized. Centrocin 1 is a
heterodimer formed by monomers of 30 (heavy chain)
and 12 amino acid residues (light chain) connected by asingle disulphide bridge (Li et al. 2010). Synthesis and
subsequent antimicrobial testing of the different mono-
mers showed that the cationic heavy chain is equally ac-
tive as the original dimeric peptide. On the other hand,
the neutral light chain showed no antimicrobial activity
(Li et al. 2010). Helical wheel projection of the heavy
chain indicates that this sequence has an amphipathic
structure, a feature common for many membrane-active
AMPs. Interestingly, centrocin 1 heavy chain contains a
brominated tryptophan on position two (Li et al. 2010)
with unknown function.
In the present study, centrocin 1 heavy chain (CEN1
HC-Br) and derivatives thereof, were synthesised and
screened for in vitro bactericidal activity against selected
microbial strains in four different assay media. The pep-
tides were also evaluated for in vitro anti-inflammatory
properties as measured by inhibition of secretion of
tumor necrosis factor alpha (TNF-α) and interleukin-6
(IL-6) from lipopolysaccharide (LPS) stimulated macro-
phages derived from the monocytic cell line THP-1, and
for their cytotoxicity to the same cells. The debromi-
nated analogue of centrocin 1 heavy chain, CEN1 HC,
was evaluated for its ability to reduce bacterial counts in
two different infected wound models, an in vivo excision
wound model in rats, and an ex vivo pig skin model. In
addition, resistance development against CEN1 HC was
assessed in the bacterial strains S. aureus and MRSA.
Materials and methods
Peptides and antibiotics
The heavy chain of centrocin 1 (CEN1 HC-Br), the C-
terminal truncated peptide (CEN1 HC-Br (1–20)) and
its debrominated equivalent (CEN1 HC (1–20)) were
purchased from BIOMOL International LP (Exeter, UK).
The non-halogenated heavy chain CEN1 HC and an
analogue where the free cysteine in position 25 is
exchanged with serine, CEN1 HC (Ser), were purchased
from Biopeptide Co., Inc. (San Diego, CA). The peptides
(Table 1) were all synthesised using Fmoc solid phase
technology, and the peptide content and purity were
determined by high performance liquid chromatography
(HPLC) and mass spectrometry (MS) analysis. The bro-
minated peptides were all synthesised with 5-Bromo-D/
L-tryptophan in position 2. Mupirocin (Bactroban, 2%
ointment, GlaxoSmithKline, Brentford, UK) and fusidic
acid (Fucidin, 2% cream, LEO Pharma, Malmö, Sweden)
were used as comparators in assessment of in vitro
microbicidal effect. In the in vitro resistance assay,
mupirocin (Applichem, Darmstadt, Germany) in powder
form was used as comparator.
In vitro microbicidal effect
All the synthesised peptides were tested for their in vitro
microbicidal activity against S. aureus (American Type
Table 1 Amino acid sequence of centrocin 1 heavy chain (CEN1 HC-Br) and its synthetic fragments and analogues
Peptide Sequence Net charge at pH = 7.0 Ratio hydrophobic/total residues
CEN1 HC-Br GW(Br)FKKTFHKVSHAVKSGIHAGQRGCSALGF + 5.2 53%
CEN1 HC GWFKKTFHKVSHAVKSGIHAGQRGCSALGF + 5.2 53%
CEN1 HC-Br (1–20) GW(Br)FKKTFHKVSHAVKSGIHA + 4.3 60%
CEN1 HC (1–20) GWFKKTFHKVSHAVKSGIHA + 4.3 60%
CEN1 HC (Ser) GWFKKTFHKVSHAVKSGIHAGQRGSSALGF + 5.3 50%
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(ATCC 15442) using a minimal microbicidal concentra-
tion (MMC) assay as previously described (Haversen
et al. 2010). Bacteria were cultured in 3.7% brain heart
infusion (BHI) broth (Difco, BD Diagnostics, Franklin
Lakes, NJ) on a shaker at 250 rpm overnight at 37°C.
The culture was diluted 1:10 in fresh 3.7% BHI and incu-
bated for two additional hours to reach log-phase
growth. The bacteria were pelleted by centrifugation at
900 × g and suspended in 0.037% BHI to a concentration
of 107 CFU/mL, estimated by measuring optical density
at 600 nm (OD600). To investigate the influence of
physiological conditions on microbicidal effect of the
peptides, four different assay media were used: 0.037%
BHI, 0.037% BHI supplemented with 85 or 150 mM
sodium chloride (NaCl), and 50% heat inactivated simu-
lated wound fluid (h.i. SWF) composed of a 50:50 mix-
ture of 0.1% peptone (Oxoid, Basingstoke, UK) in 150
mM NaCl and fetal bovine serum (FBS; PAA Laborato-
ries GmbH, Pasching, Austria), diluted two times in
ultra pure water. The peptides were serially diluted by
twofold steps from 200 to 1.56 mg/L in the assay media
used, and 100 μL of the peptide solutions were mixed
with 5 μL bacterial suspensions in a 96 well plate (Nunc,
Roskilde, Denmark) and incubated at 37°C for two
hours. An aliquot of 5 μL from each well was aspirated
and added as drops onto blood agar plates (Columbia
agar; Oxoid, Basingstoke, UK) supplemented with 5%
defibrinated horse blood (Swedish National Veterinary
Institute (SVA), Uppsala, Sweden), and the plates were
incubated overnight at 37°C. All samples were processed
as duplicates. The minimal test compound concentration
causing ≥99% reduction of bacteria was defined as the
MMC99. The concentration of the bacterial suspension
used in the assay was confirmed by viable count estima-
tion on blood agar plates (Oxoid).
CEN1 HC was further screened for microbicidal activity
against a panel of microbial strains using the MMC99 assay,
as described above, except using only two different assay
media; 0.037% BHI and 50% h.i. SWF. The following micro-
bial strains were tested for sensitivity: S. aureus (ATCC
12600), MRSA (ATCC 33591), Staphylococcus epidermidis
(ATCC 12228), Streptococcus pyogenes (ATCC 12344),
Propionibacterium acnes (ATCC 6919) Escherichia coli
(ATCC 11775), P. aeruginosa (ATCC 15442), Klebsiellapneumoniae (Culture collection, University of Gothenburg
(CCUG) 59413, clinical isolate resistant to penicillins,
cephalosporins, aztreonam and carbapenems, with the
reference strain ATCC 13883), Acinetobacter baumannii
(CCUG 58437, clinical isolate resistant to tobramycin, trim-
sulfa, ciprofloxacin, cefotaxim, ceftazidim, meropenem,
pipera/tazobactam, with the reference strain ATCC 19606)
and the yeast strain Candida albicans (ATCC 64549).
Mupirocin (GlaxoSmithKline) and fusidic acid (LEO
Pharma) were used as comparative control antibiotics.
In vitro anti-inflammatory effect
The human monocytic cell line THP-1 (ATCC TIB-202)
was cultured in RPMI 1640 medium (PAA Laboratories
GmbH) supplemented with 10% FBS (PAA Laboratories
GmbH), 1 mM sodium pyruvate (Sigma-Aldrich, St.
Louis, MO), and 20 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES; PAA Laboratories
GmbH). The cell density was adjusted to 106 cells/mL
and 100 μL of the cell suspension was added to each
well of 96 well plates (Sarstedt, Nümbrecht, Germany).
The cells were treated with 10 ng/mL phorbol
12-myristate 13-acetate (PMA; Sigma-Aldrich) to differ-
entiate the monocytes into macrophage-like cells. After
48 h, the cells were stimulated by adding 0.1 ng/mL LPS
into the medium specified above, except that 10% FBS
was replaced with 5% h.i. FBS. The LPS concentration
used was selected based on in vitro titration experiments
to give a close to maximum release of cytokines into the
cell culture medium over a period of six hours (data not
shown). The indicated concentrations of the peptides
were added 30 min after addition of LPS. After six hours
of incubation, the plates were centrifuged for six min-
utes at 400 × g and the supernatants were collected and
kept frozen at −20°C until analysed for TNF-α and IL-6
production. The cytokine levels were analysed using
enzyme-linked immunosorbent assay (ELISA; R&D Sys-
tems, Minneapolis, MN).
In vitro cytotoxic effect on THP-1 cells assessed by TACS
MTT assay
THP-1 cells were cultured, differentiated, stimulated and
the peptides were added as described above. Triton X-
100 (ICN Biomedicals Inc., OH) was used as a positive
control, and added at the same time as the peptides.
Björn et al. AMB Express 2012, 2:67 Page 4 of 12
http://www.amb-express.com/content/2/1/67After six hours of incubation, TACS MTT (3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide)
assay (R&D Systems) was performed according to the
manufacturer’s instructions. In short, 10 μL MTT re-
agent was added to each well and the plates were incu-
bated for two hours at 37°C. Subsequently, 100 μL
detergent reagent (100 mg/L) was added and the plates
were incubated in dark at room temperature overnight.
The plates were shaken for 10 min at 300 rpm and the
absorbance at 570 nm with the reference wavelength
650 nm was measured.
In vitro resistance assay
S. aureus (ATCC 12600) and MRSA (ATCC 33591) were
cultured according to the protocol described above and
diluted to 108 CFU/mL in 0.037% BHI as estimated by
measuring OD600. The multistep resistance assay was
performed as previously described (Kosowska-Shick
et al. 2006). Peptide dilutions were prepared in twofold
dilution steps in the concentration range from 0.75
mg/L to 96 mg/L in a volume of 1 mL using 0.37% BHI
medium. The same peptide concentration range was
used during all passages and new peptide dilutions were
prepared each day from stock solutions. Mupirocin
(Applichem), the active substance in the conventional
topical antibiotic Bactroban, was used as a comparator.
The antibiotic control was handled in the same way as
the peptides except that the concentration range of
mupirocin was 0.003 mg/L to 3 mg/L.
An aliquot of 10 μL (108 CFU/mL) of the bacterial
suspension was added to the peptide dilutions, to the
positive antibiotic control, and to a negative control
incubated without peptide, and the suspensions were
incubated at 37°C for 24 h. Turbidity of the overnight
cultures was determined by OD600 measurements. The
OD600 of bacteria/peptide suspensions was calculated
by subtracting the OD600 of the peptide mixed with
medium from the OD600 measured on the overnight
cultures. To create an optimal selection pressure, the
overnight culture having the highest peptide concentra-
tion without marked reduction of bacterial viability
(defined as OD600 value of >85% compared to the value
measured for the negative control sample) was further
passed.
The bacteria/peptide suspension to be further passed
was diluted in 0.37% BHI to 108 CFU/mL. A volume of
10 μL (108 CFU/mL) from the selected inoculum was
transferred to vials with 1 mL fresh peptide solutions
diluted in 0.37% BHI. The suspensions were incubated
at 37°C for 24 h. The same procedure was performed
with the antibiotic control. The remaining bacterial sus-
pensions were centrifuged at 900 × g for ten minutes,
then resuspended in a 50:50 mixture of 3.7% BHI and
80% glycerol and immediately frozen at −80°C and keptfrozen until analysis. The 24-h incubation and inocula-
tion procedure described above was repeated for 14 days.
MMC99 assay was performed, as described above, on the
overnight cultures after 0, 1, 4, 7 and 14 passages to
evaluate resistance induction.
In vivo excision wound model in rats
The ability of CEN1 HC and CEN1 HC (Ser) to reduce
bacterial counts was estimated in an excision wound
model in rat designed based on previously published
studies (Gisby and Bryant 2000; McRipley and Whitney
1976; Rittenhouse et al. 2006; Saymen et al. 1972).
Briefly, female Sprague–Dawley rats (200–250 g, Charles
River Laboratories, Sulzfeldt, Germany) were housed at
the Laboratory of Experimental Biomedicine, Gothenburg,
Sweden. They were kept in a 12-h light–dark cycle and
were cared for in accordance with regulations for the pro-
tection of laboratory animals. All animal experiments were
performed after prior approval from the local Ethics Com-
mittee for Animal Studies at the Administrative Court of
Appeals in Gothenburg, Sweden. The rats were acclima-
tised in cages for a minimum of five days before surgery,
with four rats in each cage. They had free access to water
and pellets (Lab For, Lantmännen, Sweden). The rats were
anaesthetised during the whole experiment and the anaes-
thesia was induced by an intra-peritoneal injection of a
mixture of fentanyl (272 μg/kg; B. Braun Melsungen AG,
Melsungen, Germany) and medetomidine hydrochloride
(545 μg/kg; Domitor, Orion Pharma Animal Health AB,
Sollentuna, Sweden). The backs of the rats were shaved
and swabbed with 70% chlorhexidine alcohol (Fresenius
Kabi AB, Uppsala, Sweden). Six 10 mm× 10 mm full thick-
ness wounds were made, separated by the distance of
5 mm. Bacteria were prepared according to the same proto-
col as described above and diluted to 2 × 109 CFU/mL. The
wounds were seeded with 20 μL of either MRSA (ATCC
33591) or P. aeruginosa (ATCC 10145) for the treatment
with CEN1 HC, and with 20 μL of MRSA (ATCC 33591)
for the treatment with CEN1 HC (Ser). Two hours after in-
fection, 100 μL of peptide in H2O (0.1–2 mg/mL) or pla-
cebo (H2O) was added to each wound. The treatment was
randomised for all wounds. All animals were euthanized
two hours after treatment by an overdose of pentobarbital
sodium (Pentobarbital vet, APL, Stockholm, Sweden). To
estimate bacterial counts, the whole wound area was dis-
sected and transferred to a micro-centrifuge tube and
placed on ice. A volume of 500 μL of Kligman buffer (0.1%
Triton X-100 in 0.075 M phosphate buffer, pH 7.9) was
added and the tube was vortexed for two minutes, followed
by shaking for ten minutes at 1400 rpm. Each suspension
was diluted in four tenfold serial steps in diluted
Kligman buffer (0.05% Triton X-100 in 0.0375 M
phosphate buffer, pH 7.9). Aliquots of 50 μL from
each of the four dilutions were seeded on blood agar
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containing 30–300 CFU were counted. All personnel
involved in the surgery, harvesting the bacteria and
counting the plates were blinded to the different
treatments.
Ex vivo model using pig skin
The ability of CEN1 HC and CEN1 HC (Ser) to re-
duce bacterial counts was estimated in an ex vivo
wound model using pig skin as previously described
(Schmidtchen et al. 2009). The pigs used in the study
were a mixed breed of Yorkshire, Hampshire and Swedish
Pigham. The pig was shaved after euthanization and
skin from the back was removed, packed in plastic foil
and frozen at −20°C for storage. Before the experiment,
the skin was taken out from the freezer and the subcuta-
neous fat was removed with a scalpel. The skin was put
in a petri-dish with Kleenex paper tissues (Kimberly Clark
GmbH, Koblenz, Germany) in the bottom, wetted with
sterile H2O, and cleaned with 70% ethanol. Punch biop-
sies were made, approximately 0.5–1 mm in thickness
and 3 mm in diameter. The top cylinder of a cut
1.5 mL micro-centrifuge tube (diameter approximately
9 mm) was glued around each punch wound with
ethyl cyanoacrylate glue (Loctite super glue gel,
Henkel Norden, Stockholm, Sweden). The area inside
the cylinder was washed two times with 250 μL of
sterile H2O.
Bacteria were cultured according to the same protocol
as described above and diluted to a concentration of
107 CFU/mL. A volume of 100 μL of the S. aureus
(ATCC 12600) suspension was applied to the wound
area. The lid of the petri-dish was applied to create a
moist chamber, and the skin was incubated for two
hours at 37°C. A volume of 100 μL peptide solutions in
H2O (0.1–2 mg/mL) or placebo (H2O) was added to the
infected area and the sample was incubated for another
four hours at 37°C. The liquid in the cylinder was
removed and the remaining bacteria were harvested by
adding 210 μL of Kligman buffer (0.1% Triton X-100 in
0.075 M phosphate buffer, pH 7.9) and the skin and
wound inside the cylinder was scratched with a plastic
loop using moderate force. The suspension was trans-
ferred to a micro-centrifuge tube, the procedure was
repeated once and the two fractions of liquid from the
infected area were pooled. The suspensions were
diluted in four tenfold serial steps in diluted Kligman
buffer (0.05% Triton X-100 in 0.0375 M phosphate buf-
fer, pH 7.9) and an aliquot of 50 μL from each dilution
was seeded on horse blood agar plates (Oxoid). The
plates were incubated at 37°C for 24 h and plates con-
taining 30–300 CFUs were counted. All personnel
involved in the surgery, harvesting the bacteria andcounting the plates were blinded to the different
treatments.Statistical analysis
The data is presented as % of the control group ± SEM
(%). The results were analysed with Student’s t-test, with
a value of p < 0.05 considered statistically significant.
Grubb’s test was performed to statistically identify out-
liers (Grubbs 1969).Results
In vitro microbicidal effect of peptides derived from
centrocin 1
An MMC99 assay was used to examine the ability of cen-
trocin 1 heavy chain (CEN1 HC-Br), its debrominated
analogue (CEN1 HC), and the C-terminal truncated var-
iants of both peptides, i.e. CEN1 HC-Br (1–20) and
CEN1 HC (1–20) to kill bacteria in vitro. In order to
characterize the functional significance of a free cysteine
residue in the sequence of centrocin 1 heavy chain, the
cysteine to serine substituted variant CEN1 HC (Ser)
was also included. The sequences of the peptides are
shown in Table 1. The concentration that killed ≥99%
bacteria was defined as MMC99. The experiments were
performed using 0.037% BHI, which is the most com-
monly used media in this type of assessment. To mimic
the physiological conditions in wounds, the data
obtained in 0.037% BHI were complemented with
experiments using 0.037% BHI supplemented with
monovalent cations (85 mM or 150 mM NaCl), as well
as using 50% of h.i. SWF.
All peptides evaluated exerted similar microbicidal ac-
tivities in 0.037% BHI against S. aureus and P. aerugi-
nosa (MMC99 = 12.5–25.0 mg/L; Table 2a and b). For
CEN1 HC-Br and CEN1 HC, addition of monovalent
cations (85 mM or 150 mM NaCl) to 0.037% BHI
resulted in somewhat reduced microbicidal effect against
S. aureus (MMC99 = 25.0–50.0 mg/L), while no reduc-
tion in effect was observed against P. aeruginosa, com-
pared to 0.037% BHI only. For CEN1 HC-Br (1–20),
CEN1 HC (1–20) and CEN1 HC (Ser), physiological-like
sodium chloride concentrations completely abolished
the bactericidal effect against S. aureus (MMC99 ≥
200 mg/L) and reduced the effect against P. aeruginosa
(MMC99 = 12.5–100.0 mg/L). When the MMC99 assay
was performed in 50% h.i. SWF, the MMC99 values for
CEN1 HC-Br and CEN1 HC were elevated to 25.0–
50.0 mg/L for S. aureus and 100.0 mg/L for P. aerugi-
nosa. No bactericidal effect was observed against S. aur-
eus or P. aeruginosa with CEN1 HC-Br (1–20), CEN1
HC (1–20), and CEN1 HC (Ser) at concentrations up to
200 mg/L, when 50% h.i. SWF was used as assay
medium (Table 2a and b).
Table 2 Microbicidal effect of CEN1 HC-Br, CEN1 HC, CEN1 HC-Br (1–20), CEN1 HC (1–20) and CEN1 HC (Ser) against S.
aureus (a) and P. aeruginosa (b)
(a)
S. aureus, medium and MMC99 (mg/L)
Test substance 0.037% BHI 0.037% BHI + 85 mM NaCl 0.037% BHI + 150 mM NaCl 50% SWF
CEN1 HC-Br 25 25 50 50
CEN1 HC 12.5 25 50 25
CEN1 HC-Br (1–20) 12.5 >200 >200 >200
CEN1 HC (1–20) 12.5 >200 >200 >200
CEN1 HC (Ser) 25 >200 >200 >200
(b)
P. aeruginosa, medium and MMC99 (mg/L)
Test substance 0.037% BHI 0.037% BHI + 85 mM NaCl 0.037% BHI + 150 mM NaCl 50% SWF
CEN1 HC-Br 25 12.5 25 100
CEN1 HC 12.5 12.5 12.5 100
CEN1 HC-Br (1–20) 12.5 12.5 25 >200
CEN1 HC (1–20) 12.5 25 100 >200
CEN1 HC (Ser) 12.5 25 50 >200
The substances were tested using a MMC99 assay in concentrations up to 200 mg/L in four different assay media. Peptides were added to bacterial cells in
duplicate (n = 2). Data are presented as maximum values from at least two independent experiments. h.i. = heat inactivated.
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uated against a panel of Gram-positive bacteria (S. aur-
eus, MRSA, S. pyogenes, S. epidermidis, and P. acnes)
and Gram-negative bacteria (E. coli, P. aeruginosa,
K. pneumoniae, and A. baumannii) as well as the yeast
C. albicans. The results demonstrated that 3.1–6.3 mg/L
or 6.3–100 mg/L of CEN1 HC was required to kill ≥99%
of all the bacterial strains in 0.037% BHI broth and 50%
h.i. SWF, respectively, indicating a broad range of micro-
bicidal activities against both Gram-positive and Gram-
negative bacteria assessed in both media. Interestingly,
the ability to kill the yeast strain C. albicans appears to
be impaired in 50% h.i. SWF (MMC99 ≥ 200 mg/L). The
MMC99 values for CEN1 HC compared to theTable 3 Microbicidal effect of CEN1 HC against Gram-positive
CEN1 HC MMC99 (mg/L)
Microorganism, strain 0.037% BHI 50% h.i. SWF 0
S. aureus ATCC 12600 6.3 12.5
MRSA ATCC 33591 6.3 25
S. pyogenes ATCC 12344 3.1 50
S. epidermidis ATCC 12228 3.1 12.5
P. acnes ATCC 6919 6.3 12.5
E. coli ATCC 11775 6.3 25
P. aeruginosa ATCC 15442 6.3 100
K. pneumoniae CCUG 59413 3.1 12.5
A. baumannii CCUG 58437 3.1 6.3
C. albicans ATCC 64549 6.3 >200
The substances were tested using a MMC99 assay in concentrations up to 200 mg/L
duplicate (n = 2). Data are presented as maximum values from at least two indepenconventional antibiotics mupirocin (GlaxoSmithKline)
and fusidic acid (LEO Pharma) are shown in Table 3.
In vitro anti-inflammatory effects of peptides derived
from centrocin 1
The anti-inflammatory effect of CEN1 HC-Br, CEN1
HC, CEN1 HC (1–20) and CEN1 HC (Ser) was studied
in macrophages derived from the human monocytic cell
line THP-1. All peptides tested demonstrated a signifi-
cant reduction in the release of the pro-inflammatory
cytokine TNF-α in LPS-stimulated cells. However, the
half maximal inhibitory concentration (IC50) value was
markedly higher for the truncated variant CEN1 HC
(1–20), compared to the other peptides (Figure 1a-d,and Gram-negative bacterial strains and a yeast strain
fusidic acid MMC99 (mg/L) mupirocin MMC99 (mg/L)
.037% BHI 50% h.i. SWF 0.037% BHI 50% h.i. SWF
6.3 6.3 3.1 3.1
6.3 6.3 3.1 3.1
>200 >200 6.3 3.1
6.3 6.3 3.1 3.1
nd nd >200 >200
>200 >200 >200 >200
>200 >200 >200 >200
>200 >200 >200 >200
>200 >200 >200 >200
>200 >200 >200 >200
in 0.037% BHI or 50% h.i. SWF. Peptides were added to bacterial cells in
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Figure 1 Effects of CEN1 HC-Br (a), CEN1 HC (b), CEN1 HC (1–20) (c) and CEN1 HC (Ser) (d) on TNF-α secretion from THP-1 cells. The
peptides were added to PMA treated THP-1 cells in triplicate 30 min after the addition of LPS (0.1 ng/mL). Peptide concentrations ranging from
0.04 to 50 mg/L of CEN1 HC and CEN1 HC-Br, 0.04 to 500 mg/L of CEN1 HC (Ser) and 1 to 500 mg/L of CEN1 HC (1–20) were tested. Cytokine
levels were measured in the cell supernatants by ELISA after six hours of stimulation. Data are presented as mean ± SEM with stimulated cytokine
levels without peptide added set to 0%. Data was fitted to curves using a 4-parameter fit in the Origin software. The IC50 values were
automatically calculated by the software. Due to an unsatisfactory curve fitting, IC50 for CEN1 HC-Br was estimated to be approximately 4 mg/L.
Björn et al. AMB Express 2012, 2:67 Page 7 of 12
http://www.amb-express.com/content/2/1/67Table 4). In line with these results, the peptides CEN1
HC-Br, CEN1 HC, CEN1 HC (1–20) reduced the pro-
duction of another inflammation marker, IL-6, in LPS-
stimulated cells, with the effect of CEN1 HC-Br and
CEN1 HC being more pronounced compared to the
truncated variant CEN1 HC (1–20) (Figure 2a-c, Table 4).
In these experiments, the peptides were added to the cell
culture medium 30 min after addition of LPS. Based on
previous findings, this time interval should be sufficient
for LPS to bind to the cell receptor and thus, to exclude
that the peptide would neutralize the effect of LPS on
cytokine production only by scavenging this agent(Elass-Rochard et al. 1998; Haversen et al. 2000). To rule
out the possibility that the reduction in cytokine produc-
tion by these peptides was related to peptide-induced
decline in cell viability, the cell survival was measured
after six hours of LPS-stimulation. The amount of viable
cells after the treatment with CEN1 HC, CEN1 HC
(1–20), and CEN1 HC (Ser) was approximately 90% of
the cells treated with LPS only, indicating that addition
of the peptides at concentrations up to 125 mg/L, did
not show any significant cytotoxic effect. CEN1 HC-Br
demonstrated higher cytotoxicity compared to the other
peptides as the concentration of 100 mg/L reduced the
Table 4 Inhibitory effects of CEN1 HC-Br, CEN1 HC, CEN1
HC (1–20) and CEN1 HC (Ser) on TNF-α and IL-6 secretion
from THP-1 cells
IC50 (mg/L)
Test substance TNF-α IL-6
CEN1 HC-Br ~4.0 0.0040 ± 0.053
CEN1 HC 2.2 ± 0.4 0.33 ± 0.14
CEN1 HC (1–20) 141.4 ± 18.4 9.8 ± 8.6
CEN1 HC (Ser) 6.0 ± 2.4 nd
Data are presented as half maximal inhibitory concentration (IC50) values ±
SEM, as calculated by Origin software from dose–response curves using a
4-parameter fit. Due to an unsatisfactory curve fitting, IC50 for CEN1 HC-Br on
TNF-α was estimated to approximately 4 mg/L. nd = not determined.
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shown).
In vitro resistance development towards CEN1 HC
The potential for resistance development against CEN1
HC was evaluated in two strains of Gram-positive bac-
teria, S. aureus and MRSA, by multistep dilution assay,
and compared to the antibiotic mupirocin. For both
strains the concentration of mupirocin killing ≥99% of
the bacteria was significantly increased during 14 days of
cultivation (from 3 to 24 mg/L for S. aureus and from 3
to >384 mg/L in MRSA). On the other hand, the con-
centration of CEN1 HC killing ≥99% of the bacteria was
increased only twofold comparing values at day 0 and 14
(from 6 to 12 mg/L for both S. aureus and MRSA),
which is within the limits of assay variation.
Antimicrobial effect of CEN1 HC and CEN1 HC (Ser) in
infected wound models
In order to study a potential topical antimicrobial effect
of CEN1 HC and CEN1 HC (Ser), an in vivo rat excision
wound model and an ex vivo pig skin model were used.
In the rat excision wound model full thickness wounds
were infected with MRSA or P. aeruginosa, subsequently
treated with peptide CEN1 HC or placebo (H2O), and
bacterial counts were estimated two hours after the
treatment. No animal death or local reactions in connec-
tion to the application of the test article were observed
during the experimental period. CEN1 HC potently
reduced the level of both bacterial strains in this model
(Figures 3, 4). The effect of CEN1 HC (Ser) was evalu-
ated only in wounds infected with MRSA, and this pep-
tide failed to significantly reduce bacterial counts in this
model (data not shown).
In the pig skin ex vivo study, punch biopsies were
made on the skin from the back of pigs. The wounded
areas were seeded with S. aureus, treated with CEN1
HC, CEN1 HC (Ser) or placebo (H2O), and bacterial
counts were estimated four hours after treatment. As
demonstrated in Figure 5, CEN1 HC reduced the levelof bacteria in this model in a dose dependent manner.
Treatment with CEN1 HC at the concentration of 0.5
and 2 mg/mL reduced bacterial counts with 98 and 99%,
respectively, compared to the placebo treatment. Treat-
ment with CEN1 HC (Ser) also significantly reduced the
amount of bacteria. However, the effect was less pro-
nounced compared to CEN1 HC (2 mg/mL of CEN1
HC (Ser) reduced bacterial counts with 67%, Figure 5).
Discussion
The treatment of infectious diseases poses major chal-
lenges for healthcare systems worldwide due to rapid in-
crease in bacterial strains resistant to conventional
antibiotics. AMPs have emerged as novel promising
agents for both topical and systemic treatment of infec-
tions. The AMPs are considered less prone to resistance
development than conventional antibiotics due to the
rapid microbicidal effect combined with broad mode of
action (Fjell et al. 2012).
Drug development based on AMPs is complicated by
the fact that the antimicrobial activities of numerous
naturally occurring AMPs are antagonised by physio-
logical salt concentrations, which might reflect the in-
creasing ionic strength under high salt conditions
weakening the electrostatic charge interactions of AMPs
with bacterial membranes (Tam et al. 2002). Thus,
attempts are directed towards developing therapeutic
AMPs where salt-resistant properties are achieved
through chemical modifications of the peptide structure
(Fjell et al. 2012; Park et al. 2004; Tam et al. 2002). Pep-
tides isolated from marine organisms, that are adapted
to salt-rich environments, are likely to be less sensitive
to ionic strength, and are therefore highly interesting
from a drug development perspective.
In this study, the peptide previously isolated from coe
lomocyte (blood cell) extracts of the green sea urchin,
S. droebachiensis, centrocin 1 heavy chain (CEN1 HC-Br)
(Li et al. 2010) and the variants thereof, were evaluated
for the potential as novel anti-infectious agents by meas
uring their antibacterial and anti-inflammatory effect
in vitro. CEN1 HC-Br contains a brominated tryptophan
in position two in the amino acid sequence (Li et al.
2010) with unknown function. AMPs containing bromi-
nated tryptophan have previously been characterized
from several marine organisms such as hagfish intestinal
antimicrobial peptides (HFIAPs), isolated from Atlantic
hagfish or styelin D, isolated from tunicate Styela clava
(Taylor et al. 2000; Uzzell et al. 2003). It has been specu-
lated that the unusual amino acid bromotryptophan
makes these AMPs less susceptible to proteolytic deg-
radation and may increase the biological activity of the
peptide (Li et al. 2010). To elucidate the functional sig-
nificance of the bromination of the tryptophan residue,
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Figure 2 Effects of CEN1 HC-Br (a), CEN1 HC (b) and CEN1 HC (1–20) (c) on IL-6 secretion from THP-1 cells. The peptides were added to
PMA treated THP-1 cells in triplicate 30 min after the addition of LPS (0.1 ng/mL). Peptide concentrations ranging from 0.04 to 50 mg/L of CEN1
HC and CEN1 HC-Br, and 1 to 500 mg/L CEN1 HC (1–20) were tested. Cytokine levels were measured in the cell supernatants by ELISA after six
hours of stimulation. Data are presented as mean ± SEM with stimulated cytokine levels without peptide added set to 0%. Data was fitted to
curves using a 4-parameter fit in the Origin software. The IC50 values were automatically calculated by the software.
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the peptide region necessary of the biological activity,
the C-terminal truncated variants of both peptides,
CEN1 HC-Br (1–20) and CEN1 HC (1–20), were also
tested. A free cysteine residue in the peptide sequence
may potentially complicate the product development
process due to the possible heterogeneity of the product
caused by formation of disulphide bonds between mole-
cules. Therefore, we investigated if the cysteine residue
in CEN1 HC (position 25) could be replaced by a similar
amino acid. The most commonly used replacement for
cysteine is serine, which in terms of geometry andvolume occupancy is a highly isosteric analogue of cyst-
eine. A cysteine to serine modified variant of CEN1
HC, CEN1 HC (Ser), was compared for microbicidal
and anti-inflammatory properties to its non-substituted
equivalent.
When the CEN1 HC-Br derived peptides were evalu-
ated for anti-bacterial activity against S. aureus and
P. aeruginosa, all peptides showed pronounced micro-
bicidal effect in assay medium containing low salt
concentrations and no serum (0.037% BHI). The pep-
tides CEN1 HC-Br and CEN1 HC were generally salt































Figure 3 In vivo bacterial clearance of MRSA from excision
wounds in rats after treatment with CEN1 HC. Wounds infected
with MRSA (4 × 107 CFU) were treated with CEN1 HC, in
concentrations of 0.1, 0.5, and 2 mg/mL, and sampling/bacterial
counting was performed two hours later. Results are presented as
mean relative bacterial survival (%) ± SEM compared to the non-
treated control group (n = 14 for all the groups, except for the
group treated with 0.5 mg/mL CEN1 HC, where n = 15). One value
in each group, except for the group treated with 0.5 mg/mL of
CEN1 HC, were considered outliers (p < 0.01, Grubbs’ test) and were
































Figure 4 In vivo bacterial clearance of P. aeruginosa from
excision wounds in rats after treatment with CEN1 HC. Wounds
infected with P. aeruginosa (4 × 107 CFU) were treated with CEN1
HC, in concentrations of 0.1, 0.5, and 2 mg/mL, and sampling/
bacterial counting was performed two hours later. Results are
presented as mean of relative bacterial survival (%) ± SEM compared
to the non-treated control group (n = 15 for all the groups).
** = p < 0.01, *** = p < 0.001.
Figure 5 Ex vivo bacterial clearance of S. aureus from pig skin
wounds after treatment with CEN1 HC and CEN1 HC (Ser).
Wounds infected with S. aureus (106 CFU) were treated with
CEN1 HC, in concentrations of 0.1, 0.5 and 2 mg/mL, and
sampling/bacterial counting was performed four hours after
treatment. Results are presented as mean of relative bacterial
survival (%) ± SEM compared to the non-treated control group
(n = 10 for all groups except for the groups treated with 0.5 and
2 mg/mL of CEN1 HC (Ser), where n = 9). One outlier (p < 0.01,
Grubbs’ test) was discarded from each of the groups treated
with 0.5 and 2 mg/mL CEN1 HC (Ser). * = p < 0.05, ** = p < 0.01,
*** = p < 0.001 comparing CEN1 HC to the control group,
$ = p < 0.05, $$$ = p < 0.001 comparing CEN1 HC (Ser) to the
control group.
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NaCl and in 50% h.i. SWF. Notably, physiological sodium
chloride concentrations as well as h.i SWF severely
decreased or fully eliminated the bactericidal effect of
CEN1 HC-Br (1–20), CEN1 HC (1–20) and CEN1 HC
(Ser). The microbicidal effect of the peptides and their sen-
sitivity to physiological-like conditions varied dependently
on the bacterial strain tested, possibly due to differences
between the cell wall/membrane properties of the Gram-
positive (S. aureus) and Gram-negative (P. aeruginosa)
bacteria. Interestingly, debromination of tryptophan in
CEN1 HC-Br did not impair the bactericidal effect in
neither condition of low salt nor under physiological-like
conditions.
The anti-inflammatory properties of CEN1 HC-Br,
CEN1 HC, CEN1 HC (1–20) and CEN1 HC (Ser) were
evaluated by measuring secretion of the most commonly
used inflammation markers TNF-α and IL-6 in human
monocyte derived macrophages stimulated with LPS.
In this assay, CEN1 HC-Br, CEN1 HC and the Ser-
substituted peptide CEN1 HC (Ser) exerted a more
potent anti-inflammatory effect compared to the C-
terminal truncated variant CEN1 HC (1–20). No obvious
difference in efficacy was seen comparing CEN1 HC-Br
and CEN1 HC, while the first peptide had higher cyto-
toxicity compared to the debrominated equivalent.
Based on these experiments, we conclude that debro-
mination of the tryptophan residue of CEN1 HC-Br did
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conditions tested. Importantly, CEN1 HC had a more
favourable safety profile compared to the original pep-
tide, with no lytic activity observed against mammalian
cells at the concentrations tested, thus showing a clear
dissociation of antibacterial and anti-eukaryotic cell ac-
tivities. C-terminal truncation of the full-length peptide
variants resulted in reduction in salt-tolerability of
the microbicidal effect as well as in reduced anti-
inflammatory properties. Also, the peptide with the free
cysteine residue, CEN1 HC had improved salt and serum
tolerability profile in the MMC99 assay compared to the
serine-modified equivalent. Based on these observations,
it was concluded that from the panel of peptide variants
tested, CEN1 HC showed the best efficacy and safety
profile. Thus, CEN1 HC was selected to be further evalu-
ated for its in vitro and in vivo antimicrobial properties.
CEN1 HC was shown to have broad microbicidal ef-
fect against microorganisms appearing in topical and
parenteral infections including Gram-positive bacteria
(S. aureus, S. pyogenes, S. epidermidis, and P. acnes),
Gram-negative bacteria (E. coli, P. aeruginosa, K. pneu-
monia, and A. baumannii) and the yeast C. albicans.
CEN1 HC also showed pronounced effect against the
pathogen MRSA. Importantly, during the cultivation of
14 days, the bacterial strains tested (S. aureus and
MRSA) failed to develop significant resistance towards
CEN1 HC, indicating that these strains could not cir-
cumvent the action of this AMP, while significant resist-
ance profile was observed toward the conventional
antibiotic mupirocin used as comparator.
CEN1 HC demonstrated marked effect on reducing
bacterial counts in infected wound models in two dif-
ferent animal species. In a rat model of infected full
thickness excision wounds, treatment by CEN1 HC sig-
nificantly reduced the bacterial counts of MRSA as well
as P. aeruginosa, the most common pathogens in top-
ical infections in man. The antibacterial effect against
S. aureus was confirmed in an infected wound model
in pig skin. In line with the in vitro tests, CEN1 HC (Ser)
had markedly lower efficacy in these two animal models,
compared to the cysteine-containing equivalent.
In summary, we demonstrate that CEN1 HC, a chem-
ically synthesised 30 amino acid peptide sequentially
derived from the previously described AMP centrocin 1,
has a broad spectrum microbicidal effect, resistant to
physiological salt concentration and serum containing
wound fluid, combined with anti-inflammatory action.
Importantly, S. aureus and MRSA failed to develop re-
sistance against this peptide. CEN1 HC significantly
reduced bacterial counts of S. aureus, MRSA and P. aer-
uginosa in animal models of infected wounds. Based on
this study, CEN1 HC appears to be a promising agent in
the topical treatment of infections, and further studiesare warranted to evaluate the applicability of this AMP
in clinical settings.
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